ABPI Board of Management

As a member organisation, we are led by our members who are actively involved in all the core areas of our activity, as well as helping to form the strategy and direction for the ABPI.

The ABPI Board of Management comprises of individuals who are elected by members to represent the industry; and up to five people who are co-opted by the Board. Elections commence every January for elected seats to ensure that the Board is fully representative and has access to the broadest range of skills and expertise possible.

Our current Board of Management includes:

ABPI President, Jonathan Emms, UK Managing Director, Pfizer
  • President, AstraZeneca UK Limited
  • Managing Director, British & Irish Isles, UCB Pharma Limited
  • General Manager, Actelion Pharmaceuticals UK Limited
  • Director, Market Access & Corporate Affairs, Pfizer Limited
  • President, Global Value & Access Unit, Eisai Europe Limited
  • Executive Director – Western Europe, Alliance Pharmaceuticals Limited
  • Managing Director, Lilly UK, Eli Lilly & Company Limited
  • General Manager, Novartis Pharmaceuticals UK Limited
  • Managing Director, Janssen UK/Ireland, Janssen-Cilag Limited
  • General Manager, Amgen Limited
  • VP & Country General Manager UK & Ireland, Shire Pharmaceuticals Limited
  • VP UK & Ireland, Novo Nordisk Limited
  • General Manager, UK & Ireland, Bristol-Myers-Squibb Pharmaceuticals Limited
  • SVP & Managing Director, Merck Sharp & Dohme Limited
  • Managing Director, UK & Ireland, Sanofi Limited
  • General Manager, AbbVie Limited
  • Managing Director, Lundbeck Limited
  • General Manager UK & SVP UK & Ireland Pharmaceuticals, GSK
Print this page icon Print this page
Please choose the subject of your enquiry from the list below:
Code to enter for submitting the form
Enter the above code here:
Can't read? Try different words.